Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2018 07:24 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Present at Upcoming Investor Conferences

STOUGHTON, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company focused on becoming the leader in responsible pain management by...
November 08, 2018 16:05 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Reports Third Quarter Financial Results

Net Product Revenues were $70.2 million for the third quarter of 2018, a 487% increase versus third quarter of 2017Thirteen exclusive ER oxycodone formulary wins announced for Xtampza ER effective...
October 29, 2018 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER

STOUGHTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the publication of “Evaluation of the oral human abuse potential of Oxycodone...
October 17, 2018 08:30 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update

STOUGHTON, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday,...
September 28, 2018 14:16 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Present at Upcoming Investor Conference

STOUGHTON, Mass., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will present at the following investor conference in October: The...
September 04, 2018 10:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Announces Scientific Presentations at PAINWeek 2018 Meeting

STOUGHTON, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has supported the following poster presentations on tapentadol (Nucynta® and...
August 08, 2018 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Reports Second Quarter Financial Results and Provides Corporate Update

Net revenue $73.1 million for the second quarter of 2018, 1,952% increase vs second quarter 2017, 15% vs first quarter 2018Xtampza ER prescriptions grew by 23% in the second quarter of 2018Cash...
July 20, 2018 13:06 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update

CANTON, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August...
July 10, 2018 07:30 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Announces Promotion of Scott Dreyer to CCO

CANTON, Mass., July 10, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the promotion of Scott Dreyer to the position of Executive Vice President and Chief...
June 04, 2018 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Announces CEO Succession

Joseph Ciaffoni Promoted to CEO and Appointed to Board Michael Heffernan Continues to serve as Chairman of the Board CANTON, Mass., June 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc....